Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 5004Neoplasms 4197Prostatic Neoplasms 2428Carcinoma, Non-Small-Cell Lung 2265Colorectal Neoplasms 2053Lung Neoplasms 1705Multiple Myeloma 1459Lymphoma 1405Leukemia, Myeloid, Acute 1382Neoplasm Metastasis 1374Melanoma 1270Pancreatic Neoplasms 1200Leukemia 1196Ovarian Neoplasms 1192Lymphoma, Non-Hodgkin 1132Precursor Cell Lymphoblastic Leukemia-Lymphoma 1091Head and Neck Neoplasms 1056Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 897Colonic Neoplasms 895Brain Neoplasms 876Stomach Neoplasms 857Recurrence 853Carcinoma, Hepatocellular 846Glioblastoma 841Lymphoma, Large B-Cell, Diffuse 771Rectal Neoplasms 759Uterine Cervical Neoplasms 728Carcinoma, Renal Cell 705Hodgkin Disease 698

Interventions

Rituximab 2dexamethasone acetate 1Dexamethasone 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × Opsoclonus-Myoclonus Syndrome × Clear all
NCT01868269 2025-02-03

Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

Institut Curie

Phase 3 Completed
102 enrolled
CNS

Neuroblastoma, Opsoclonus-Myoclonus Syndrome

NCT00244361 2011-05-10

Effectiveness of Rituximab in Pediatric OMS Patients.

National Pediatric Neuroinflammation Organization, Inc.

Phase 1/2 Completed
25 enrolled

Ataxia, Myoclonus, Ocular Motility Disorders, Opsoclonus-Myoclonus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡